How many clinical trials are studying NXP900?

3 recruiting trials in our tracked data involve NXP900.

What conditions is NXP900 being studied for?

In our tracked recruiting trials, NXP900 is being studied in trials for Lung cancer, ALK Positive, ALK Positive Non-small Cell Lung Cancer.

Recruiting trials

Conditions studied

US states with sites

Countries

Phase 1 3

Condition	Trials
Lung cancer · NXP900 for Lung cancer	3
ALK Positive	1
ALK Positive Non-small Cell Lung Cancer	1
ALK+ Non-Small-Cell Lung Carcinoma	1
Advanced Solid Tumor	1
EGFR Mutated Non-small Cell Lung Cancer Patients	1
EGFR Mutation Positive Non-small Cell Lung Cancer	1
Mesothelioma	1
NSCLC	1
NSCLC (Non-small Cell Lung Cancer)	1
Non-Small Cell Squamous Lung Cancer	1
Non-small Cell Lung Adenocarcinoma	1
Renal Cancer	1

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
NCT05873686 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 15 locations
Study of NXP900 With Lorlatinib in ALK+ Lung Cancer
NCT07784959 · Phase: Phase 1 · Ages: No age limits stated · Sex: All (male and female) · 1 location
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
NCT07315113 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations